CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 43 enrolled
Drug / intervention
celecoxib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00698204
NCT00698204Phase 2Completed
CompareCT.gov

Cyclooxygenase-2 Inhibition in Radiation-Induced Oral Mucositis

UConn Health·interventional·Posted Jun 17, 2008·Updated Jun 5, 2014

In Brief

A Phase 2 clinical trial evaluating celecoxib and placebo for Oral Mucositis. Completed, enrolled 43 participants across 2 sites.

Detailed Summary

Oral mucositis refers to ulcerative lesions of the oral mucosa that occur due to radiation therapy given for treatment of head and neck cancer. These lesions are painful, compromise nutrition and quality of life and may necessitate interruptions in radiation therapy, thus adversely affecting cancer therapy outcomes. This study examined the use of an anti-inflammatory medicine to reduce pain and severity of oral mucositis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOral Mucositis
CountriesUnited States
CollaboratorsNational Institute of Dental and Craniofacial Research (NIDCR), Pfizer

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 17, 2008
Enrollment StartJul 1, 2003
Primary CompletionSep 1, 2012
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9.2 yearsPosted 18.0 years ago

Interventions

celecoxibdrug

Subject was asked to take celecoxib each day that radiation therapy was given.

placebodrug

Subject was asked to take placebo each day that radiation therapy was given.